Edward B. Garon, MD, MS, reviews data from the EVOKE-02 study, and the panel offers their thoughts on antibody-drug conjugates for the treatment of advanced NSCLC.
In this episode of How This Is Building Me, Drs Camidge and Garon discuss the differences in lung cancer management and drug advancement between the United States and Asia and highlight other topline takeaways from the 2023 WCLC.
Los Angeles, California (PRWEB) April 26, 2023 UCLA Technology Development Group (UCLA TDG) announced today that Albert Bourla, Chairman and CEO of Pfizer
Edward B. Garon, MD, MS, discusses challenges associated with the incorporation of immunotherapy into the treatment paradigm for EGFR-mutant non–small cell lung cancer.